{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:26Z","timestamp":1786466426008,"version":"build-2736575974"},"reference-count":78,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>For the past decades, treatment for von Willebrand disease has essentially consisted of classic approaches, and only in the past few years has the need for more innovative strategies been recognized. To address the needs of groups of patients with similar phenotypes and bleeding, personalized therapeutic strategies are being developed, molecules designed for other bleeding disorders are being repositioned, and new hemostatic agents are being tested in patients with von Willebrand disease. New therapeutics include a variety of molecules, including antibodies, engineered factors, synthetic nanoparticles, small interfering RNAs, and genome editing tools. Some promising molecules are still undergoing preclinical testing, whereas others have already entered clinical evaluation and may soon be available for at least some patients with von Willebrand disease. We believe that new approaches will improve the clinical management and the quality of life for patients with von Willebrand Disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016488","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:55:46Z","timestamp":1780606546000},"page":"5253-5263","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Novel therapies for von Willebrand disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-9156","authenticated-orcid":false,"given":"C\u00e9cile V.","family":"Denis","sequence":"first","affiliation":[{"name":"1Laboratory for Hemostasis, Inflammation & Thrombosis, INSERM UMR-S1176, University Paris-Saclay, Le Kremlin-Bic\u00eatre, France"},{"name":"2Centre Hospitalier R\u00e9gional Universitaire de Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hachem","family":"Dich","sequence":"additional","affiliation":[{"name":"1Laboratory for Hemostasis, Inflammation & Thrombosis, INSERM UMR-S1176, University Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6795","authenticated-orcid":false,"given":"Caterina","family":"Casari","sequence":"additional","affiliation":[{"name":"1Laboratory for Hemostasis, Inflammation & Thrombosis, INSERM UMR-S1176, University Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"17","key":"2026081110262556200_bib1","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood.2020008501","article-title":"von Willebrand disease: what does the future hold?","volume":"137","author":"Denis","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026081110262556200_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/hae.14655","article-title":"Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: systematic and targeted literature reviews","volume":"29","author":"Castaman","year":"2023","journal-title":"Haemophilia"},{"issue":"4","key":"2026081110262556200_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3324\/haematol.2024.286076","article-title":"A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options","volume":"110","author":"McCluskey","year":"2024","journal-title":"haematol"},{"issue":"21","key":"2026081110262556200_bib4","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood.2025029401","article-title":"A bispecific nanobody for the treatment of von Willebrand disease type 1","volume":"146","author":"Peyron","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026081110262556200_bib5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/ATVBAHA.117.309319","article-title":"A novel single-domain antibody against von Willebrand factor A1 domain resolves leukocyte recruitment and vascular leakage during inflammation\u2014brief report","volume":"37","author":"Aym\u00e9","year":"2017","journal-title":"ATVB"},{"issue":"11","key":"2026081110262556200_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2018-01-829523","article-title":"A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation","volume":"132","author":"Muczynski","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026081110262556200_bib7","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/bloodadvances.2025018516","article-title":"HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease","volume":"10","author":"H\u00e4ger","year":"2026","journal-title":"Blood Adv"},{"issue":"S1","key":"2026081110262556200_bib8","first-page":"24","article-title":"Elevating levels of endogenous circulating von Willebrand factor (VWF): the potential of HMB-002 as a prophylactic treatment of von Willebrand disease","volume":"31","author":"Ostergaard","year":"2025","journal-title":"Haemophilia"},{"issue":"S2","key":"2026081110262556200_bib9","first-page":"127","article-title":"HMB-002: elevating von Willebrand Factor for prophylactic treatment of von Willebrand disease","volume":"9","author":"Zivkovic","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"S2","key":"2026081110262556200_bib10","first-page":"307","article-title":"Favorable nonclinical safety profile of HMB-002 for prophylactic treatment of von Willebrand disease","volume":"9","author":"Rasmussen","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"S2","key":"2026081110262556200_bib11","first-page":"3","article-title":"VELORA Pioneer: first-in-human safety and PK\/PD study of HMB-002 in type 1 von Willebrand disease","volume":"9","author":"Raheja","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"S3","key":"2026081110262556200_bib12","first-page":"17","article-title":"First-in-human study of HMB-002: a subcutaneous antibody for prophylactic management of von Willebrand disease","volume":"31","author":"Raheja","year":"2025","journal-title":"Haemophilia"},{"issue":"suppl 2","key":"2026081110262556200_bib13","first-page":"102503","article-title":"VGA039, a protein S-targeting monoclonal antibody, demonstrates in a phase Ia healthy volunteer trial the potential of subcutaneous weekly or less frequent prophylactic dosing for bleeding disorders OC 73.3","volume":"8","author":"Schoergenhofer","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026081110262556200_bib14","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2024-208020","article-title":"A phase Ia study of VGA039, a protein S-targeting monoclonal antibody, in individuals with von Willebrand disease demonstrates concentration-dependent increases in thrombin generation for reducing bleeding","volume":"144","author":"Millar","year":"2024","journal-title":"Blood"},{"issue":"S3","key":"2026081110262556200_bib15","first-page":"11","article-title":"Phase I study Of Vga039 in individuals with von Willebrand disease demonstrates sustained drug concentrations, increased thrombin generation, and decreased bleeding after single subcutaneous injection","volume":"31","author":"Millar Carolyn","year":"2025","journal-title":"Haemophilia"},{"issue":"S1","key":"2026081110262556200_bib16","first-page":"153","article-title":"A phase I study of VGA039, a protein S-targeting monoclonal antibody, in individuals with von Willebrand disease demonstrates sustained drug concentrations, increased thrombin generation and decreased bleeding following a single subcutaneous injection","volume":"31","author":"Millar","year":"2025","journal-title":"Haemophilia"},{"issue":"21","key":"2026081110262556200_bib17","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood.2025031186","article-title":"Nanobody treatment of von Willebrand disease","volume":"146","author":"O\u2019Donnell","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2026081110262556200_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.14755","article-title":"The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer","volume":"18","author":"Zhu","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026081110262556200_bib19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.str.2009.09.011","article-title":"A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1","volume":"17","author":"Huang","year":"2009","journal-title":"Structure"},{"issue":"9","key":"2026081110262556200_bib20","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","article-title":"The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial","volume":"107","author":"Kovacevic","year":"2021","journal-title":"haematol"},{"issue":"13","key":"2026081110262556200_bib21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2024024055","article-title":"The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1","volume":"144","author":"Chion","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026081110262556200_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1538-7836.2009.03459.x","article-title":"Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779","volume":"7","author":"Diener","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"09","key":"2026081110262556200_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1160\/TH10-01-0027","article-title":"A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease","volume":"104","author":"Paulinska","year":"2010","journal-title":"Thromb Haemost"},{"issue":"08","key":"2026081110262556200_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"Jilma-Stohlawetz","year":"2012","journal-title":"Thromb Haemost"},{"issue":"18","key":"2026081110262556200_bib25","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026081110262556200_bib26","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood-2024-202611","article-title":"Rondaptivon pegol (BT200) to correct thrombocytopenia in a peri-interventional setting in type 2B von Willebrand disease (VWD)","volume":"144","author":"Moser","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026081110262556200_bib27","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med"},{"issue":"9","key":"2026081110262556200_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/jcm6090085","article-title":"Efficacy of octocog alfa (Advate) in a child with type 3 von Willebrand disease and alloantibodies","volume":"6","author":"Sottilotta","year":"2017","journal-title":"JCM"},{"issue":"3","key":"2026081110262556200_bib29","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1111\/j.1365-2516.2012.02799.x","article-title":"The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor","volume":"18","author":"Pergantou","year":"2012","journal-title":"Haemophilia"},{"issue":"2","key":"2026081110262556200_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.mbc.0000214711.19116.09","article-title":"Successful use of recombinant factor VIII devoid of von Willebrand factor during multiple teeth extractions in a patient with type 3 von Willebrand disease","volume":"17","author":"Sakurai","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2026081110262556200_bib31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jha2.984","article-title":"Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: a literature review and case report","volume":"5","author":"Briane","year":"2024","journal-title":"EJHaem"},{"issue":"02","key":"2026081110262556200_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0038-1649564","article-title":"Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease","volume":"70","author":"Morfini","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026081110262556200_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1538-7836.2003.00009.x","article-title":"Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease","volume":"1","author":"Boyer-Neumann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026081110262556200_bib34","first-page":"786","article-title":"Treatment with emicizumab leads to clinical improvement in a type 3 von Willebrand disease patient with inhibitor suffering from left ankle arthropathy","volume":"4","author":"Sigaud","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"18","key":"2026081110262556200_bib35","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2026081110262556200_bib36","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/hae.14272","article-title":"Emicizumab improves thrombus formation of type 2A von Willebrand disease under high shear condition","volume":"27","author":"Yaoi","year":"2021","journal-title":"Haemophilia"},{"key":"2026081110262556200_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2020.11.026","article-title":"Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions","volume":"198","author":"Yaoi","year":"2021","journal-title":"Thromb Res"},{"issue":"5","key":"2026081110262556200_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/hae.14581","article-title":"Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease","volume":"28","author":"Yaoi","year":"2022","journal-title":"Haemophilia"},{"key":"2026081110262556200_bib39","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.bcmd.2020.102530","article-title":"The potential role of emicizumab prophylaxis in severe von Willebrand disease","volume":"87","author":"Barg","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2026081110262556200_bib40","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3324\/haematol.11460","article-title":"Thrombin-generating capacity in patients with von Willebrand\u2019s disease","volume":"92","author":"Rugeri","year":"2007","journal-title":"Haematologica"},{"issue":"12","key":"2026081110262556200_bib41","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1016\/j.jtha.2023.09.009","article-title":"Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa","volume":"21","author":"Ryu","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026081110262556200_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jtha.2025.07.013","article-title":"A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease","volume":"24","author":"Susen","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026081110262556200_bib43","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2022-170245","article-title":"Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders","volume":"140","author":"Leong","year":"2022","journal-title":"Blood"},{"issue":"suppl 2","key":"2026081110262556200_bib44","doi-asserted-by":"crossref","first-page":"101253","DOI":"10.1016\/j.rpth.2023.101253","article-title":"PB1311 prophylactic efficacy of VGA039, an anti-protein S monoclonal antibody, in a novel non-human primate model of acquired von Willebrand disease","volume":"7","author":"Huck","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026081110262556200_bib45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2025-308","article-title":"Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: results from A phase 1\/2 multidose study of VGA039 in patients with von Willebrand disease","volume":"146","author":"Wheeler","year":"2025","journal-title":"Blood"},{"key":"2026081110262556200_bib46","doi-asserted-by":"crossref","first-page":"102663","DOI":"10.1016\/j.bcmd.2022.102663","article-title":"Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study","volume":"95","author":"Barg","year":"2022","journal-title":"Blood Cells Mol Dis"},{"issue":"03","key":"2026081110262556200_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/a-2373-2829","article-title":"An inhibitory single-domain antibody against protein Z-dependent protease inhibitor promotes thrombin generation in severe hemophilia A and FXI deficiency","volume":"125","author":"Auditeau","year":"2025","journal-title":"Thromb Haemost"},{"issue":"S1","key":"2026081110262556200_bib48","first-page":"27","article-title":"Efficacy and safety of ETX-148 in murine models of haemophilia A and B","volume":"31","author":"Pursell","year":"2025","journal-title":"Haemophilia"},{"issue":"6","key":"2026081110262556200_bib49","doi-asserted-by":"crossref","first-page":"e70084","DOI":"10.1002\/btm2.70084","article-title":"Biosynthetic blood surrogates: current status and future opportunities","volume":"10","author":"Disharoon","year":"2025","journal-title":"Bioeng Transl Med"},{"issue":"23","key":"2026081110262556200_bib50","first-page":"2891","article-title":"Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models","volume":"141","author":"Roullet","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026081110262556200_bib51","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1172\/JCI69458","article-title":"von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin \u03b1IIb\u03b23","volume":"123","author":"Casari","year":"2013","journal-title":"J Clin Invest"},{"issue":"12","key":"2026081110262556200_bib52","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/bloodadvances.2017014290","article-title":"Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets","volume":"2","author":"Casari","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026081110262556200_bib53","doi-asserted-by":"crossref","first-page":"26306","DOI":"10.1038\/srep26306","article-title":"A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation","volume":"6","author":"Adam","year":"2016","journal-title":"Sci Rep"},{"issue":"735","key":"2026081110262556200_bib54","doi-asserted-by":"crossref","first-page":"eadh0027","DOI":"10.1126\/scitranslmed.adh0027","article-title":"Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A","volume":"16","author":"Strilchuk","year":"2024","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2026081110262556200_bib55","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2024-211420","article-title":"A therapeutic siRNA targeting plasminogen acts as a long-lasting antifibrinolytic in nonhuman primates","volume":"144","author":"Strilchuk","year":"2024","journal-title":"Blood"},{"issue":"suppl 2","key":"2026081110262556200_bib56","first-page":"268","article-title":"OC 39.2 siRNA knockdown of plasminogen inhibits fibrinolysis and reduces bleeding in animal models of bleeding disorders","volume":"9","author":"Ketelboeter","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026081110262556200_bib57","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2025-3058","article-title":"Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice","volume":"146","author":"Cevasco","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026081110262556200_bib58","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"2026081110262556200_bib59","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene elaparvovec for hemophilia B - a multiyear follow-up study","volume":"392","author":"Rasko","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2026081110262556200_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jtha.2024.12.038","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","volume":"23","author":"Ozelo","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026081110262556200_bib61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jth.13938","article-title":"High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease","volume":"16","author":"Portier","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026081110262556200_bib62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2008-02-142943","article-title":"Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa","volume":"112","author":"Marx","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2026081110262556200_bib63","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1161\/ATVBAHA.108.168369","article-title":"Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease","volume":"28","author":"De Meyer","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"2026081110262556200_bib64","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1182\/blood-2009-11-253120","article-title":"Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions","volume":"115","author":"Golder","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2026081110262556200_bib65","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1182\/blood-2005-09-3605","article-title":"Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor","volume":"107","author":"De Meyer","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2026081110262556200_bib66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2011.238","article-title":"In vivo gene transfer strategies to achieve partial correction of von Willebrand disease","volume":"23","author":"Wang","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"3-4","key":"2026081110262556200_bib67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther"},{"issue":"12","key":"2026081110262556200_bib68","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1016\/j.ymthe.2025.09.027","article-title":"Correction of VWF multimerization in type 2A\/IIC von Willebrand disease by exogenous VWF propeptide supplementation","volume":"33","author":"Zhang","year":"2025","journal-title":"Mol Ther"},{"issue":"2","key":"2026081110262556200_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(88)90511-9","article-title":"The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers","volume":"52","author":"Wise","year":"1988","journal-title":"Cell"},{"issue":"24","key":"2026081110262556200_bib70","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2010-02-268920","article-title":"The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation","volume":"116","author":"Casari","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2026081110262556200_bib71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jth.15131","article-title":"In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A","volume":"19","author":"Campioni","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026081110262556200_bib72","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/jth.14140","article-title":"Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor","volume":"16","author":"de Jong","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026081110262556200_bib73","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1055\/s-0040-1715442","article-title":"Ex vivo improvement of a von Willebrand disease Type 2A phenotype using an allele-specific small-interfering RNA","volume":"120","author":"De Jong","year":"2020","journal-title":"Thromb Haemost"},{"issue":"20","key":"2026081110262556200_bib74","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/bloodadvances.2023010643","article-title":"Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in vitro and in vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026081110262556200_bib75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/bloodadvances.2024014601","article-title":"Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs","volume":"9","author":"Linthorst","year":"2025","journal-title":"Blood Adv"},{"issue":"6669","key":"2026081110262556200_bib76","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"1","key":"2026081110262556200_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2026081110262556200_bib78","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2025018760","article-title":"Allele-selective disruption of pathogenic VWF variants in type 2 von Willebrand disease using CRISPR\/Cas9","volume":"10","author":"B\u00e4r","year":"2026","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5253\/2535685\/blooda_adv-2025-016488-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5253\/2535685\/blooda_adv-2025-016488-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:46Z","timestamp":1786463026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5253\/568875\/Novel-therapies-for-von-Willebrand-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":78,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016488","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,30]]}}}